Survival in patients with Parkinson's disease: a ten-year follow

Background A thorough understanding of the factors that influence patient survival in Parkinson’s disease (PD) will aid in prognosis prediction and provide a new direction for disease modification treatment. Currently, there are no standardized mortality ratio (SMR) data for PD patients in the northern Chinese mainland. The main focus of this study was to determine which factors in the prospectively collected baseline characteristics can affect the survival of PD patients. In addition, for the first time, we investigated the SMR of PD patients in northern China. Methods Between 2009 and 2012, 218 PD patients were continuously recruited from the movement disorder clinic of the First Affiliated Hospital of Dalian Medical University and followed up until death or May 31, 2021. The prespecified prognostic variables were demographics, clinical features, lifestyle factors, and drug dose prospectively collected at baseline. To determine the independent predictors of survival during follow-up, the Cox proportional hazards model was used. Kaplan–Meier analysis was applied to estimate the overall survival curve and to compare survival between layers based on statistically significant predictors. The SMR of this northern Chinese mainland PD cohort was calculated. Results After a mean follow-up of 9.58 ± 2.27 years, 50 patients (22.90%) died. Factors that could individually predict shortened survival during follow-up included older age at onset (hazard ratio [HR] 1.10, 95% confidence interval [CI] 1.06–1.15), Hoehn and Yahr (H&Y) stage ≥ 3 (HR 9.36, 95% CI 2.82–31.03) and severe cognitive impairment (HR 6.18, 95% CI 2.75–13.88). Univariate Cox regression revealed that a certain amount of physical activity was associated with better survival (HR 0.41, 95% CI 0.22–0.74), while fatigue was associated with an increased risk of death (HR 2.54, 95% CI 1.37–4.70). The overall SMR was 1.32 (95% CI 0.98–1.74). Conclusions Older age at onset, higher baseline H&Y stage, and severe cognitive impairment have a negative impact on survival. The 10-year survival of PD patients is not significantly different from that of the general population in China.

Why did 250,000 Britons die sooner than expected?

The elephant in the room: critical reflections on mortality rates among individuals with Parkinson's disease

Number of People Diagnosed with Parkinson's Increases to Nearly 90,000 Each Year

The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years

Third-party bone marrow–derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial - American Journal of Transplantation

Parkinson's Foundation Launches National Program for People Newly Diagnosed with Parkinson's Disease

PDF) Survival in patients with Parkinson's disease: a ten-year follow-up study in northern China

Falling PSA levels found to predict longer survival in prostate cancer patients at high risk of metastases

Spotlight debate—should we worry that pimavanserin might increase mortality amongst patients with Parkinson's disease psychosis?

First delirium episode in Parkinson's disease and parkinsonism: incidence, predictors, and outcomes

Early onset Parkinson's: Symptoms, causes, and treatment

Ten-Year Survivorship, Patient-Reported Outcome Measures, and Patient Acceptable Symptom State After Over-the-Top Hamstring Anterior Cruciate Ligament Reconstruction With a Lateral Extra-articular Reconstruction: Analysis of 267 Consecutive Cases

Parkinson's disease - Wikipedia

Could Alzheimer's disease be a maladaptation of an evolutionary survival pathway mediated by intracerebral fructose and uric acid metabolism? - The American Journal of Clinical Nutrition